Glenmark Generics (GGL), a subsidiary of Glenmark Pharmaceuticals, (Q, N,C,F)* has received final approval from the US Food and Drug Administration (USFDA) to market Lamotrigine tablet, in the strengths of 5 mg and 25 mg.

Lamotrigine is used for the treatment of partial seizures and for long-term management of bipolar disorder.

Recently, the company received a final approval from the US Food and Drug Administration (USFDA) to market Lithium Carbonate Capsules in the strengths of 150mg, 300 mg and 600 mg.

Shares of the company closed down Rs 0.65, or 0.47%, at Rs 137.25. The total volume of shares traded at the BSE was 333,182 (Friday).